New LaunchApr 14, 2026, 08:02 AM
Amneal Launches 2 Inhalation Products, Entering $1.8B Market
AI Summary
Amneal Pharmaceuticals announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, both FDA-approved in 2025. These are the company's first metered-dose inhalation (MDI) products, marking its entry into the complex inhalation category. The albuterol product is a generic equivalent of PROAIR® HFA, with annual sales of approximately $1.5 billion, while the beclomethasone product is a generic equivalent of QVAR® Inhalation Aerosol, with annual sales of about $321 million. This strategic move expands Amneal's respiratory platform and addresses patient access gaps.
Key Highlights
- Amneal launched albuterol sulfate inhalation aerosol, a generic equivalent of PROAIR® HFA.
- The company also launched beclomethasone dipropionate HFA inhalation aerosol, a generic of QVAR® Inhalation Aerosol.
- These are Amneal's first two metered-dose inhalation (MDI) product launches in the U.S.
- The albuterol product had U.S. annual sales of approximately $1.5 billion.
- The beclomethasone product had U.S. annual sales of approximately $321 million.